LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Lista de Ações・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Fechado

SetorSaúde

1.35 -4.26

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.34

Máximo

1.44

Indicadores-chave
By Trading Economics
Rendimento	-2.4M -40M
Vendas	6.2M 45M
Margem de lucro	-90.427
Funcionários	485
EBITDA	-6M -38M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+68.79% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-74M 481M
Abertura anterior	5.61
Fecho anterior	1.35

Sentimento de Notícias

By Acuity

67%

33%

312 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

1.13 / N/A Suporte e Resistência

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de mai. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 de mai. de 2026, 23:46 UTC

Conversa de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 de mai. de 2026, 23:33 UTC

Conversa de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 de mai. de 2026, 22:37 UTC

Conversa de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 de mai. de 2026, 22:32 UTC

Ganhos

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 de mai. de 2026, 22:02 UTC

Conversa de Mercado

Notícias Principais

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 de mai. de 2026, 21:49 UTC

Ganhos

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 de mai. de 2026, 21:42 UTC

Conversa de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 de mai. de 2026, 21:31 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 de mai. de 2026, 21:23 UTC

Aquisições, Fusões, Aquisições de Empresas

CSG Systems Sale to NEC Gets CFIUS Clearance

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

11 de mai. de 2026, 20:44 UTC

Ganhos

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 de mai. de 2026, 20:43 UTC

Ganhos

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Rev $136.4M >CLSK

11 de mai. de 2026, 20:30 UTC

Ganhos

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Cont Ops EPS $2.24 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Rev $1.6B >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Adj EPS $2.83 >STE

11 de mai. de 2026, 20:22 UTC

Ações em Alta

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 de mai. de 2026, 19:37 UTC

Ganhos

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 de mai. de 2026, 19:32 UTC

Conversa de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

68.79% parte superior

Previsão para 12 meses

Média 2.38 USD 68.79%

Máximo 3 USD

Mínimo 1.5 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.13 / N/ASuporte e Resistência

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentimento

By Acuity

312 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.